


# PRODUCT INFORMATION



## SSR 69071

Item No. 21477

**CAS Registry No.:** 344930-95-6  
**Formal Name:** 2-[[6-methoxy-4-(1-methylethyl)-1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl]methoxy]-9-[2-(1-piperidinyl)ethoxy]-4H-pyrido[1,2-a]pyrimidin-4-one  
**MF:** C<sub>27</sub>H<sub>32</sub>N<sub>4</sub>O<sub>7</sub>S  
**FW:** 556.6  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 229, 271 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

SSR 69071 is supplied as a crystalline solid. A stock solution may be made by dissolving the SSR 69071 in the solvent of choice. SSR 69071 is soluble in organic solvents such as ethanol and DMSO which should be purged with an inert gas. The solubility of SSR 69071 in these solvents is approximately 10 and 25 mM, respectively.

### Description

SSR 69071 is a potent inhibitor of neutrophil elastase ( $K_i = 0.0168$  nM for the human enzyme).<sup>1</sup> It is selective for human neutrophil elastase over rat, mouse, and rabbit elastases ( $K_i$ s = 3, 1.8, 58 nM, respectively). It inhibits human neutrophil elastase *ex vivo* in mouse bronchoalveolar lavage (BAL) fluid ( $ED_{50} = 10.5$  mg/kg, p.o.). *In vivo*, SSR 69071 (2.8 mg/kg, p.o.) reduces acute lung hemorrhage induced by human neutrophil elastase in mice. It reduces carrageenan- and human neutrophil elastase-induced paw edema in rats ( $ED_{30}$ s = 2.2 and 2.7 mg/kg, respectively). SSR 69071 also reduces cardiac infarct size when administered prior to ischemia or reperfusion in a rabbit model of ischemia-reperfusion injury.<sup>2</sup>

### References

1. Kapui, Z., Varga, M., Urban-Szabo, K., *et al.* Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxyethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor. *J. Pharmacol. Exp. Ther.* **305**(2), 451-459 (2003).
2. Bidouard, J.-P., Duval, N., Kapui, Z., *et al.* SSR69071, an elastase inhibitor, reduces myocardial infarct size following ischemia - reperfusion injury. *Eur. J. Pharm.* **461**(1), 49-52 (2003).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/04/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)